期刊文献+

新型抗癌药物尼洛替尼的合成工艺研究

The synthesis of the new anticancer drugs Nilotinib
下载PDF
导出
摘要 研究尼洛替尼的合成工艺及方法。以O-甲基异脲硝酸盐为原料,与3-氨基-4-甲基苯甲酸酯在醇类溶剂中反应得到3-胍基4-甲基苯甲酸酯硝酸盐,然后再和3-(二甲基氨基)-1-(3-吡啶基)-2-丙烯-1-酮环化生成嘧啶胺衍生物。在金属有机化合物存在下,中间体和3-氨基-5-溴三氟甲苯发生胺解反应得到,最后,再和4-甲基咪唑进行碳氮偶联反应得到尼洛替尼。通过1H NMR,IR和元素分析,表征了目标产物的结构,与尼洛替尼一致。该合成方法路线简捷、绿色环保、成本低、反应条件较温和。 To study on the synthetic method of Nilotinib. The reaction of O-methylisourea nitrate as raw materi- als, with methyl 3-amino-4-methylbenzoate in an alcoholic solvent to afford 3-guanidino-4-methylbenzoate ni- trate, and then, the cyclization reaction of intermediate with 3-(dimethylamino) -1-(3-pyridyl) -2-propen-1- one gave a pyrimidine amine derivative. In the presence of metal organic compound, the aminolysis reaction of intermediates with 3-amino-5-bromobenzotrifluoride occured. Finally, Nilotinib was synthetised by the carbon and nitrogen coupling reaction of with 4-methyl imidazole. By 1H NMR, IR and elemental analysis, the struc- ture of target product was characterized, consistent with the results of Nilotinib. This method is simple with milder reaction conditions, low cost, and is environmental friendly.
出处 《西北大学学报(自然科学版)》 CAS CSCD 北大核心 2015年第4期590-594,共5页 Journal of Northwest University(Natural Science Edition)
基金 陕西省教育厅产业化培育基金资助项目(2011JG03)
关键词 O-甲基异脲硝酸盐 3-氨基-5-溴三氟甲苯 3.氨基-4-甲基苯甲酸甲酯 尼洛替尼 O-methylisourea nitrate 3-amino-5-bromobenzotrifluoride methyl 3-amino4-methyl benzoate guanidine Nilotinib
  • 相关文献

参考文献13

  • 1DEREMER D L, USTUN C, NATARAJAN K. Nilo- tinib: A second-generation tyrosine kinaseInhibitor for the treatment of chronic myelogenous leukemia [ J ]. Clinical Therapeutics, 2008, 30( 11 ) : 1956-1975.
  • 2BRECCIA M, ALIMENA G. Nilotinib: A second-gen- eration tyrosine kinase inhibitor for chronic myeloid leukemia[ J ]. Leukemia Research, 2010, 34 : 129- 134.
  • 3ZHOU L, MENG F Y, YIN O, et al. Nilotinib for Imatinib-resistant or-intolerant chronic myeloid leuke- mia in chronic phase, accelerated phase, or blast cri- sis: A single-and multiple-dose, open-label pharmaco- kinetic study in Chinese patients [ J ]. Clinical Thera- peutics, 2009, 31 (7) : 1568-1575.
  • 4JORGENSEN H G, ALLAN E K, JORDANIDES N E, et al. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD3d+ CML cells[J]. Blood, 2007, 109: 4016- 4019.
  • 5周励,沈志祥.慢性髓性白血病治疗新药尼洛替尼[J].中国新药杂志,2010,19(17):1496-1499. 被引量:7
  • 6BREITENSTEIN W, FURET P, JACOB S, et al. In- hibitors of tyrosine kinases: WO, 2004005281 [ P]. 2004-01-15.
  • 7MCKENNA J, SHIEH W C. Process for the synthesis of organic compounds : WO, 2006135631 [ P ~. 2006-12- 21.
  • 8陈永江,王丽华,周红,王从站.尼罗替尼的合成[J].中国医药工业杂志,2009,40(6):401-403. 被引量:7
  • 9YEORI A, WANG Y L, LI J, et al. Processes for preparation of nilotinib and intermediates : WO, 2010060074 [ P]. 2010~05-27.
  • 10HUANG W S, SHAKESPEARE W C. An efficient synthesis of nilotinib (AMN107) [ J ]. Synthesis, 2007,14 : 2121-2124.

二级参考文献23

  • 1Deininger MW. Nilotinib [J]. Clin Cancer Res, 2008, 14(13): 4027-4031. (CA2009, 150: 15552)
  • 2Jabbour E, Cortes J, Kantarjian H, et al. Drug evaluation: Nilotinib---a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond [J]. Drugs, 2007, 10(7) : 468-479. (CA 2008, 149: 69381)
  • 3Huang WS, Shakespeare WC. An efficient synthesis of nilotinib (AMNI07) [J]. Synthesis, 2007, (14) : 2121-2124. (CA 2007, 147: 448724)
  • 4Werner B, Pascal F, Sandra J, et al. Inhibitors of protein kinases: US, 2008188451 [P]. 2008-08-07; WO, 2004005281 [P]. 2003-07-04. (CA 2004, 140: 77161)
  • 5Shieh WC, McKenna J. Process for the synthesis of 5- (methyl- 1H-imidazol- 1 -yl) -3- (trifluoromethyl) bene- zeneamine: US, 2008188656 [P]. 2008-08-07; WO, 2006135641 [P]. 2006-12-21. (CA2007, 146: 81883)
  • 6ROWLEY JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining[J]. Nature, 1973, 243(5405):290 - 293.
  • 7DEININGER M, BUCHDUNGER E, DRUKER BJ. The development of irnatinib as a therapeutic agent for chronic myeloid leukemia [ J ]. Blood, 2005,105 ( 7 ) :2640 - 2653.
  • 8O'BRIEN SG, GUILHOT F, GOLDMAN JM, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response(MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib ( IM ) [ J ]. Blood, 2008, 112 : Abstr. No. 186.
  • 9WEISBERG E, MANLEY PW, BREITENSTEIN W,et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl[J]. Cancer Cell, 2005, 7(2) :129-141.
  • 10WEISBERG E, MANLEY PW, MESTAN J, et al. AMN107 (nilotinib) : a novel and selective inhibitor of BCR-ABL[ J]. Br J Cancer, 2006, 94(12) :1765 - 1769.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部